Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherClinical Investigations

Usefulness of Fasting 18F-FDG PET in Identification of Cardiac Sarcoidosis

Wataru Okumura, Tsutomu Iwasaki, Takuji Toyama, Tatsuya Iso, Masashi Arai, Noboru Oriuchi, Keigo Endo, Tomoyuki Yokoyama, Tadashi Suzuki and Masahiko Kurabayashi
Journal of Nuclear Medicine December 2004, 45 (12) 1989-1998;
Wataru Okumura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tsutomu Iwasaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takuji Toyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatsuya Iso
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masashi Arai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noboru Oriuchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keigo Endo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomoyuki Yokoyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tadashi Suzuki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masahiko Kurabayashi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Short-axis and vertical long-axis slices of myocardial PET and SPECT images were divided into 13 segments.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Comparison of nuclear measurements between histologically diagnosed cardiac sarcoidosis (HCS) and clinically diagnosed cardiac sarcoidosis (CCS). Frequency of abnormal segments on 99mTc-MIBI SPECT and TDS in HCS (white bar) was significantly higher than that in CCS (black bar) (B and D). In contrast, frequency of abnormal segments on fasting 18F-FDG PET and T-SUV in HCS were lower than those in CCS, although significant difference could be observed only for T-SUV (A and C). NS = not significant.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Relationship between nuclear measurements (T-SUV and TDS) and clinical data (LVEF and serum ACE level) in patients with cardiac sarcoidosis (group A). Statistically significant correlations were observed between TDS and LVEF (A) and between T-SUV and serum ACE level (B).

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Correlation between SUV and DS in segments with abnormal 18F-FDG uptake (A), those with abnormal 99mTc-MIBI perfusion (B), and those with abnormal 18F-FDG uptake or 99mTc-MIBI defect (C). Significant negative correlations were observed in all types of abnormal segment.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Localization of 3 types of abnormal segment.

  • FIGURE 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6.

    Fasting 18F-FDG PET images (top) and 99mTc-MIBI SPECT images (bottom) in patient 9. 18F-FDG PET revealed markedly increased uptake of 18F-FDG in segments 1–8, whereas 99mTc-MIBI SPECT revealed no abnormal findings.

  • FIGURE 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 7.

    Fasting 18F-FDG PET images (top) and 99mTc-MIBI SPECT images (bottom) in patient 1. 18F-FDG PET revealed slightly increased uptake of 18F-FDG in segments 1, 2, 4, and 12. 99mTc-MIBI SPECT clearly revealed moderate reduction of 99mTc-MIBI uptake in segments 5, 6, and 12 and severe reduction of 99mTc-MIBI uptake in segment 3.

Tables

  • Figures
    • View popup
    TABLE 1

    Characteristics of 22 Patients

    Patient no.Age (y)SexECG findingsLVEF (%)Histologic diagnosis of extracardiac sarcoidosisBlood glucose (mg/dL)Serum ACE (IU/L 37°C)
    Group A
        169MComplete AVB41Myocardium1037.4
        269FSecond AVB45Myocardium858.8
        365FST-T change, VT33Myocardium8212.3
        473FST-T change, second AVB47Intraabdominal LN9114.4
        552FCRBBB, ST-T change, VT71TBLB7612.5
        646FCRBBB + LAH, second AVB40TBLB7430.1
        755FCRBBB + LAH, first AVB, VT42Scalene node10411.1
        878FST-T change, second AVB67Scalene node9213.4
        973FSecond AVB, PSVT57Skin9422.4
        1062FCRBBB + LAH, VT47Skin7230.0
        1162FSecond AVB68Skin8118.3
    Group B
        1262FNormal71TBLB953.5
        1354FCRBBB80TBLB8519.7
        1444MNormal78TBLB7730.2
        1537FNormal60TBLB8439.3
        1656FNormal76TBLB10212.5
        1774FCRBBB82Scalene node7920.7
        1867MNormal67Scalene node10112.1
        1966FNormal67Skin9227.8
        2071FNormal68Skin7411.2
        2164FNormal75Skin8226.0
        2268FST-T change73Skin10418.0
    • ECG = electrocardiography; LVEF = left ventricular ejection fraction; ACE = angiotensin-converting enzyme; AVB = atrioventricular block; VT = ventricular tachycardia; LN = lymph node; CRBBB = complete right bundle branch block; TBLB = transbronchial lung biopsy; LAH = left anterior hemiblock; PSVT = paroxymal supraventricular tachycardia.

    • View popup
    TABLE 2

    Guidelines for Diagnosis of Cardiac Sarcoidosis from Japanese Ministry of Health and Welfare

    Criterion for diagnosis of cardiac sarcoidosis
    1: Histologic diagnosis group
        Cardiac sarcoidosis is diagnosed when histologic analysis of operative or endomyocardial biopsy specimens demonstrates epithelioid granuloma without caseating granuloma.
    2: Clinical diagnosis group
        In patients with histologic diagnosis of extracardiac sarcoidosis, cardiac sarcoidosis is diagnosed when item “a” and one or more of items “b-e” are present.
            a. Complete right bundle branch block, left-axis deviation, atrioventricular block, ventricular tachycardia, premature ventricular contraction (more than second grade of Lown’s classification), or abnormal Q or ST-T change on electrocardiogram or ambulatory electrocardiogram
            b. Abnormal wall motion, regional wall thinning or thickening, or dilatation of left ventricle on echocardiogram
            c. Perfusion defect in 201T1 myocardial scintigraphy or abnormal accumulation in 67Ga-citrate or 99mTc-pyrophosphate myocardial scintigraphy
            d. Abnormal intracardiac pressure, low cardiac output, or abnormal wall motion or depressed ejection fraction of left ventricle
            e. Interstitial fibrosis or cellular infiltration over moderate grade in endomyocardial biopsy even if findings are nonspecific
    • View popup
    TABLE 3

    SUV of 18F-FDG for Each of 13 Myocardial Segments in Healthy Volunteers

    ParameterMyocardial segment
    12345678910111213
    Mean1.941.921.891.851.871.871.981.951.941.931.931.921.86
    SD0.200.210.190.230.190.250.200.240.180.200.220.260.16
    Mean + 2 SD2.342.332.282.302.262.372.392.422.292.342.372.442.18
    • View popup
    TABLE 4

    Results of Myocardial Nuclear Imaging

    Patient no.67Ga*18F-FDG PET and 99mTc-MIBI SPECT segmental analysis†No. of abnormal segmentsT-SUV of 18F-FDGTDS of 99mTc-MIBI
    Seg. 1Seg. 2Seg. 3Seg. 4Seg. 5Seg. 6Seg. 7Seg. 8Seg. 9Seg. 10Seg. 11Seg. 12Seg. 1318F-FDG99mTc-MIBI
    Group A
        1+3.51(0)3.54(0)2.13(3)3.18(0)1.84(2)1.62(2)2.08(0)2.14(0)1.74(0)2.03(0)1.77(0)2.51(2)2.01(0)4430.19
        2+3.82(0)4.12(0)3.08(2)4.03(2)2.08(0)1.87(0)2.12(0)1.83(0)1.94(0)1.68(0)1.64(2)1.60(2)1.78(0)4431.68
        3−2.84(2)3.81(0)2.51(3)2.82(2)1.89(3)1.61(2)2.64(2)3.54(0)1.68(2)1.83(0)1.95(3)1.95(2)1.87(3)61030.924
        4−14.13(0)6.20(1)8.70(0)2.24(0)2.13(0)2.02(0)14.70(0)9.41(0)6.60(0)4.48(0)2.06(0)2.13(0)5.98(0)8180.81
        5−5.23(0)4.82(0)4.47(0)2.21(0)1.98(0)1.71(0)4.98(0)4.16(0)3.88(0)1.90(0)1.82(0)1.80(0)2.13(0)6041.10
        6+6.88(0)7.31(0)2.23(2)2.20(2)4.72(2)2.08(3)10.94(0)11.12(0)7.79(0)9.32(0)9.20(0)7.60(1)6.11(2)10687.512
        7+4.31(0)4.97(0)2.04(0)1.93(0)1.73(0)1.78(0)3.25(2)3.82(2)1.95(0)1.91(0)1.83(2)1.75(0)1.80(2)4433.18
        8−2.21(0)2.14(0)1.95(0)1.98(0)1.84(0)1.78(0)5.44(0)4.88(0)5.13(0)2.10(0)2.01(0)1.83(0)1.90(0)3035.20
        9−5.74(0)5.12(0)4.18(0)4.24(0)3.64(0)3.56(0)5.01(0)4.76(0)1.74(0)1.95(0)2.28(0)1.83(0)1.78(0)8045.80
        10−13.81(0)9.94(0)6.71(2)8.34(0)6.15(2)8.56(0)12.02(0)9.78(0)9.91(0)9.53(0)7.78(1)8.30(1)6.90(0)134117.76
        11−9.54(0)2.30(0)6.51(0)4.91(0)6.02(0)3.71(0)2.21(0)4.41(0)1.97(0)2.01(0)2.12(0)4.25(0)1.89(0)7051.90
    Sum 7333
    Group B
        12−2.10(0)1.98(0)1.88(0)1.71(0)1.76(0)1.81(0)2.14(0)2.01(0)1.98(0)1.89(0)1.74(0)1.80(0)1.89(0)0024.70
        13−1.56(0)1.61(0)1.41(0)1.53(0)1.43(0)1.45(0)1.69(0)1.79(0)1.88(0)1.61(0)1.79(0)1.78(0)2.01(0)0021.50
        14−1.78(0)1.83(0)1.88(0)1.71(0)1.63(0)1.72(0)1.97(0)1.94(0)1.93(0)2.01(0)2.11(0)2.01(0)1.79(0)0024.30
        15−1.91(0)1.82(0)1.79(0)1.85(0)1.90(0)1.85(0)2.15(0)2.08(0)2.17(0)1.83(0)1.65(0)1.72(0)1.89(0)0024.60
        16−2.18(0)2.08(0)1.92(0)1.95(0)2.08(0)1.89(0)1.82(0)1.79(0)1.70(0)1.71(0)1.94(0)1.91(0)1.99(0)0025.00
        17−1.98(0)2.17(0)1.91(0)2.05(0)1.86(0)1.99(0)1.99(0)2.09(0)1.80(0)1.82(0)1.75(0)1.72(0)1.73(0)0024.90
        18−2.04(0)1.89(0)2.15(0)2.08(0)1.87(0)1.71(0)1.65(0)1.70(0)1.88(0)1.99(0)2.11(0)1.86(0)1.98(0)0024.90
        19−1.97(0)2.13(0)2.07(0)1.78(0)2.05(0)1.90(0)2.27(0)2.29(0)2.10(0)2.15(0)2.19(0)2.29(0)1.62(0)0026.80
        20−1.72(0)1.60(0)1.85(0)1.77(0)1.88(0)2.07(0)1.91(0)1.88(0)1.67(0)1.97(0)1.99(0)1.96(0)1.97(0)0024.20
        21−2.03(0)1.99(0)2.21(0)2.08(0)2.06(0)1.99(0)1.79(0)2.11(0)2.18(0)2.20(0)2.00(0)1.99(0)1.81(0)0026.40
        22−3.11(0)2.81(0)3.13(0)2.77(0)1.91(0)2.12(0)3.30(0)3.13(0)3.10(0)3.07(0)1.81(0)1.95(0)2.10(0)8034.30
    Sum 80
    • ↵* + represents myocardial uptake of 67Ga; − represents no myocardial uptake of 67Ga.

    • ↵† Data for each segment (Seg.) are presented as SUV; score in parentheses represents DS. Boldface values represent abnormal data.

    • View popup
    TABLE 5

    Diagnostic Performance of Fasting 18F-FDG PET, 99mTc-MIBI SPECT, and 67Ga Scintigraphy

    ParameterPercentage (no. of patients)
    18F-FDG PET99mTc-MIBI SPECT67Ga scintigraphy
    Sensitivity100 (11/11)63.6* (7/11)36.4† (4/11)
    Specificity90.9 (10/11)100 (11/11)100 (11/11)
    Accuracy95.5 (21/22)81.8 (18/22)68.2* (15/22)
    • ↵* P < 0.05 vs. 18F-FDG PET.

    • ↵† P < 0.01 vs. 18F-FDG PET.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 45 (12)
Journal of Nuclear Medicine
Vol. 45, Issue 12
December 1, 2004
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Usefulness of Fasting 18F-FDG PET in Identification of Cardiac Sarcoidosis
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Usefulness of Fasting 18F-FDG PET in Identification of Cardiac Sarcoidosis
Wataru Okumura, Tsutomu Iwasaki, Takuji Toyama, Tatsuya Iso, Masashi Arai, Noboru Oriuchi, Keigo Endo, Tomoyuki Yokoyama, Tadashi Suzuki, Masahiko Kurabayashi
Journal of Nuclear Medicine Dec 2004, 45 (12) 1989-1998;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Usefulness of Fasting 18F-FDG PET in Identification of Cardiac Sarcoidosis
Wataru Okumura, Tsutomu Iwasaki, Takuji Toyama, Tatsuya Iso, Masashi Arai, Noboru Oriuchi, Keigo Endo, Tomoyuki Yokoyama, Tadashi Suzuki, Masahiko Kurabayashi
Journal of Nuclear Medicine Dec 2004, 45 (12) 1989-1998;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • THIS MONTH IN JNM
  • PubMed
  • Google Scholar

Cited By...

  • Prevalence of ventricular parasystole in patients with cardiac sarcoidosis: correlation between parasystole and inflammation in ventricular fibrillation
  • T2-weighted short-tau-inversion-recovery imaging reflects disease activity of cardiac sarcoidosis
  • Predicting risk of sudden cardiac death in patients with cardiac sarcoidosis using multimodality imaging and personalized heart modeling in a multivariable classifier
  • Myocarditis in systemic lupus erythematosus diagnosed by 18F-fluorodeoxyglucose positron emission tomography
  • Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 2 of a 2-Part Series
  • Hospitalization Rates, Prevalence of Cardiovascular Manifestations, and Outcomes Associated With Sarcoidosis in the United States
  • Joint SNMMI-ASNC Expert Consensus Document on the Role of 18F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring
  • Inter- and Intraobserver Agreement of 18F-FDG PET/CT Image Interpretation in Patients Referred for Assessment of Cardiac Sarcoidosis
  • Time Course and Factors Correlating With Ventricular Tachyarrhythmias After Introduction of Steroid Therapy in Cardiac Sarcoidosis
  • Additional Heparin Preadministration Improves Cardiac Glucose Metabolism Suppression over Low-Carbohydrate Diet Alone in 18F-FDG PET Imaging
  • Advanced Imaging of Cardiac Sarcoidosis
  • Is There an Association Between Clinical Presentation and the Location and Extent of Myocardial Involvement of Cardiac Sarcoidosis as Assessed by 18F- Fluorodoexyglucose Positron Emission Tomography?
  • SNMMI/ASNC/SCCT Guideline for Cardiac SPECT/CT and PET/CT 1.0
  • EANM/SNMMI Guideline for 18F-FDG Use in Inflammation and Infection
  • Imaging the inflammatory activity of sarcoidosis
  • The Use of 18F-FDG PET in the Diagnosis of Cardiac Sarcoidosis: A Systematic Review and Metaanalysis Including the Ontario Experience
  • Intraocular sarcoidosis: association of clinical characteristics of uveitis with findings from 18F-labelled fluorodeoxyglucose positron emission tomography
  • Monomorphic Ventricular Tachycardia and Mediastinal Adenopathy Due to Granulomatous Infiltration in Patients With Preserved Ventricular Function
  • Cardiac Sarcoidosis and Giant Cell Myocarditis as Causes of Atrioventricular Block in Young and Middle-Aged Adults
  • Undiagnosed myocardial sarcoidosis presenting as life threatening cardiac dysrhythmia
  • Heterogeneous Myocardial FDG Uptake and the Disease Activity in Cardiac Sarcoidosis
  • Ventricular tachycardia as the first manifestation of cardiac sarcoidosis
  • 18F-FDG PET scan as follow-up tool for sarcoidosis with symptomatic cardiac conduction disturbances requiring a pacemaker
  • 18F-FDG PET scan as follow-up tool for sarcoidosis with symptomatic cardiac conduction disturbances requiring a pacemaker
  • Detecting cardiac involvement in sarcoidosis: a call for prospective studies of newer imaging techniques
  • Comparative Evaluation of 18F-FDG PET and 67Ga Scintigraphy in Patients with Sarcoidosis
  • Cardiac sarcoidosis
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure
  • Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System
Show more Clinical Investigations

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire